Overcoming cancer immune tolerance and escape.
Although HER2/neu-targeted cancer vaccines have shown initial promise in the adjuvant setting, a therapeutic vaccine remains elusive due to the tumor escape mechanisms of established cancer. As described by Seavey et al. in this issue of CCR, a Listeria-delivered vaccine may help overcome immune tolerance, leading to an effective therapeutic vaccine.
Clifton
Guy T
GT
General Surgery, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA.
Peoples
George E
GE
D000276:Adjuvants, Immunologic; D000818:Animals; D001427:Bacterial Toxins / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018734:Genes, erbB-2; D005822:Genetic Vectors; D006360:Heat-Shock Proteins / Q000627:therapeutic use; D006460:Hemolysin Proteins / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance; D008089:Listeria monocytogenes / Q000276:immunology*; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000276:immunology*; D019139:Tumor Escape; D014614:Vaccines, Synthetic / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D001427:Bacterial Toxins; D019496:Cancer Vaccines; D006360:Heat-Shock Proteins; D006460:Hemolysin Proteins; D014614:Vaccines, Synthetic; C038705:hlyA protein, Listeria monocytogenes